文献速递中枢神经肿瘤放疗姑息放疗与转移瘤放疗物理与技术

AGuIX纳米颗粒作为放射增敏剂:多发性脑转移瘤I期剂量递增试验

Theranostic AGuIX nanoparticles as radiosensitizer: A phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial).
PubMed 文献 · Radiother Oncol · 2021-05-05

NANO-RAD I期试验评估了钆基纳米颗粒AGuIX联合全脑放疗治疗多发性脑转移瘤的安全性和最大耐受剂量。15例患者接受15-100 mg/kg剂量递增,未观察到剂量限制性毒性,AGuIX可靶向脑转移瘤并在瘤内滞留长达1周。

要点

  • AGuIX联合全脑放疗安全可行,至100 mg/kg未出现剂量限制性毒性。
  • AGuIX可选择性靶向脑转移瘤,瘤内滞留长达1周且浓度与剂量成比例。

核心结论

  • AGuIX联合放疗治疗脑转移瘤安全可行,AGuIX可特异性靶向脑转移瘤并在瘤内滞留长达1周,支持其放射增敏效应。

研究设计与样本

  • I期剂量递增试验(NANO-RAD),纳入多发性脑转移瘤不适合立体定向放疗的患者,AGuIX设15、30、50、75、100 mg/kg五个剂量组,每组3例,于全脑放疗(30 Gy/10次)首日静脉给药。

主要发现

  • 共纳入15例患者、354个转移灶,至AGuIX 100 mg/kg未观察到剂量限制性毒性。
  • AGuIX血浆消除半衰期各组相似,平均1.3小时(范围0.8-3小时)。
  • 在黑色素瘤、肺癌、乳腺癌和结肠癌原发患者的转移灶中观察到有效靶向(T1 MRI增强、肿瘤选择性)及AGuIX对比增强的持续存在。
  • 给药后转移灶内AGuIX浓度与注射剂量成比例。

关键数值与推荐

  • AGuIX剂量递增为15、30、50、75、100 mg/kg静脉给药,全脑放疗为30 Gy分10次。
  • 毒性评估采用NCI不良事件通用术语标准v4.03。

临床怎么用

  • 对于不适合立体定向放疗的多发性脑转移瘤患者,AGuIX联合全脑放疗可作为安全可行的治疗策略,但疗效需待正在进行的II期研究进一步确认。

局限性

  • 本文为I期剂量递增试验,样本量小(15例),主要评估安全性和最大耐受剂量,疗效需II期研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Brain metastasis impacts greatly on patients' quality of life and survival. The phase I NANO-RAD trial assessed the safety and maximum tolerated dose of systemic administration of a novel gadolinium-based nanoparticle, AGuIX, in combination with whole brain radiotherapy in patients with multiple brain metastases not suitable for stereotactic radiotherapy. MATERIALS AND METHODS: Patients with measurable brain metastases received escalating doses of AGuIX nanoparticles (15, 30, 50, 75, or 100 mg/kg intravenously) on the day of initiation of WBRT (30 Gy in 10 fractions) in 5 cohorts of 3 patients each. Toxicity was assessed using NCI Common Terminology Criteria for Adverse Events v4.03. RESULTS: Fifteen patients with 354 metastases were included. No dose-limiting toxic effects were observed up to AGuIX 100 mg/kg. Plasma elimination half-life of AGuIX was similar for all groups (mean 1.3 h; range 0.8-3 h). Efficient targeting of metastases (T1 MRI enhancement, tumor selectivity) and persistence of AGuIX contrast enhancement were observed in metastases from patients with primary melanoma, lung, breast, and colon cancers. The concentration of AGuIX in metastases after administration was proportional to the injected dose. Thirteen of 14 evaluable patients had a clinical benefit, with either stabilization or reduction of tumor volume. MRI analysis showed significant correlation between contrast enhancement and tumor response, thus supporting a radiosensitizing effect. CONCLUSION: Combining AGuIX with radiotherapy for patients with brain metastases is safe and feasible. AGuIX specifically targets brain metastases and is retained within tumors for up to 1 week; ongoing phase II studies will more definitively assess efficacy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Verry C, Dufort S, Villa J, et al. Theranostic AGuIX nanoparticles as radiosensitizer: A phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial). Radiother Oncol. 2021. PMID: 33961915. doi:10.1016/j.radonc.2021.04.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。